Comparative effectiveness of nivolumab versus clinical practice for advanced gastric or gastroesophageal junction cancer.
J Comp Eff Res
; 9(2): 103-114, 2020 01.
Article
em En
| MEDLINE
| ID: mdl-31872771
ABSTRACT
Aim:
To determine the effectiveness of nivolumab compared with routine clinical practice (RCP) for patients with gastric or gastroesophageal cancer refractory to, or intolerant of, two or more previous regimens, using real-world electronic patient records from a US population, a single-arm trial (CheckMate 032) and a randomized controlled trial in an Asian setting (ATTRACTION-2). Materials &methods:
A simulated treatment comparison was conducted to predict overall survival for patients treated with nivolumab compared with RCP in the USA.Results:
Results of the indirect simulated treatment comparison suggest that nivolumab is associated with a 50% reduction in the risk of all-cause mortality relative to RCP (Hazard ratio 0.50; 95% CI 0.36, 0.68).Conclusion:
The survival benefit of nivolumab may extend more generally to the USA.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
/
Neoplasias Esofágicas
/
Junção Esofagogástrica
/
Nivolumabe
Tipo de estudo:
Clinical_trials
/
Evaluation_studies
/
Prognostic_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article